Capricor Therapeutics, Inc. (CAPR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
Capricor Therapeutics is a pre-commercial biotechnology company developing Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD), with a BLA under FDA review targeting a PDUFA date of August 22, 2026. The company has no approved products and finances operations... Read more
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierdonor hearts and other raw materials10-K Item 1A: 'the manufacturing of our product candidates is dependent on complex supply chains, including the availability of donor hearts and other raw materials that are critical'
- HIGHCustomerNippon Shinyaku10-K Item 1A: 'we will depend on the ability of Nippon Shinyaku ... to successfully commercialize Deramiocel'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $31.62. Score 4.7/10, moderate confidence.
Take-profit target: $47.56 (+39.9% upside). Prior stop was $31.62. Stop-loss: $31.62.
Concentration risk — Supplier: donor hearts and other raw materials; Concentration risk — Customer: Nippon Shinyaku; Quality below floor (1.4 < 4.0).
Capricor Therapeutics, Inc. trades at a P/E of N/A (forward -52.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover CAPR with a consensus score of 4.2/5. Average price target: $55.
What does Capricor Therapeutics, Inc. do?Capricor Therapeutics is a pre-commercial biotechnology company developing Deramiocel, a cell therapy for Duchenne...
Capricor Therapeutics is a pre-commercial biotechnology company developing Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD), with a BLA under FDA review targeting a PDUFA date of August 22, 2026. The company has no approved products and finances operations through equity offerings, government grants, and distribution agreement payments.